[1]刘果果,龙卫平,石 磊,等.小柴胡汤合炙甘草汤治疗新型冠状病毒感染相关性心肌炎临床研究[J].陕西中医,2024,(12):1634-1639.[doi:DOI:10.3969/j.issn.1000-7369.2024.12.010]
　LIU Guoguo,LONG Weiping,SHI Lei,et al.Observation on the effect of Xiaochaihu decoction combined with Zhigancao decoction in intervening myocarditis associated with novel coronavirus infection[J].,2024,(12):1634-1639.[doi:DOI:10.3969/j.issn.1000-7369.2024.12.010]
点击复制

小柴胡汤合炙甘草汤治疗新型冠状病毒感染相关性心肌炎临床研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年12期
页码:
1634-1639
栏目:
临床研究
出版日期:
2024-12-05

文章信息/Info

Title:
Observation on the effect of Xiaochaihu decoction combined with Zhigancao decoction in intervening myocarditis associated with novel coronavirus infection
作者:
刘果果; 龙卫平; 石 磊; 曹雪倩; 朱仕现
(广西中医药大学第三附属医院 柳州市中医医院心病科,广西 柳州545001)
Author(s):
LIU Guoguo; LONG Weiping; SHI Lei; CAO Xueqian; ZHU Shixian
(The Third Affiliated Hospital of Guangxi University of Chinese Medicine,Liuzhou Traditional Chinese Medical Hospital,Liuzhou 545001,China)
关键词:
病毒性心肌炎;  小柴胡汤;  炙甘草汤;  心肌损伤;  心脏功能;  中医症候
Keywords:
Viral myocarditis;  Xiaochaihu decoction;  Zhigancao decoction;  Myocardial injury;  Cardiac function;  TCM symptoms
分类号:
R 542.2
DOI:
DOI:10.3969/j.issn.1000-7369.2024.12.010
文献标志码:
A
摘要:
目的:探讨小柴胡汤合炙甘草汤干预新型冠状病毒(COVID-19)感染相关病毒性心肌炎(VMC)的临床疗效。方法:选取COVID-19相关VMC患者60例,采用随机对照原则分为对照组和观察组,各30例。对照组给予曲美他嗪、辅酶Q10、维生素C等治疗,观察组在此基础上加用小柴胡汤合炙甘草汤治疗,疗程均为4周。分别在治疗后2、4周,对比两组心肌损伤指标、心功能指标、炎症指标、心律失常疗效、中医症候疗效、不良事件发生率。结果:治疗后2、4周,观察组心肌损伤标志物肌酸激酶同工酶(CKMB)、肌钙蛋白(cTnI)、谷草转氨酶(AST)均优于对照组(均P<0.05); 心功能指标N末端-B型利钠肽前体(NT-proBNP)、左室收缩指数(LVEF)、左室舒张期末径(LVEDD)优于对照组(均P<0.05); 炎症指标C反应蛋白(CRP)、血沉(ESR)、白介素-6(IL-6)、铁蛋白(SF)、淋巴细胞计数(LY)优于对照组(均P<0.05)。观察组心律失常总有效率为70.00%和83.33%,高于对照组的46.67%和63.33%(均P<0.05); 观察组中医症候总有效率为76.67%和93.33%,高于对照组的56.67%与70.00%(均P<0.05)。结论:小柴胡汤合炙甘草汤治疗COVID-19相关VMC,可改善患者心肌损伤,保护心脏功能,降低炎症反应,改善心律失常。
Abstract:
Objective:To investigate the clinical effect of Xiaochaihu decoction and Zhigancao decoction on novel coronavirus(COVID-19)associated viral myocarditis(VMC).Methods:Sixty COVID-19 related VMC patients were selected and randomly divided into a control group and an observation group,with 30 patients in each group.The control group was treated with trimetazidine,coenzyme Q10,vitamin C,while the observation group was treated with Xiaochaihu decoction combined with Zhigancao decoction on this basis.The treatment course is all 4 weeks.Myocardial injury index,cardiac function index,inflammation index,arrhythmia effect,TCM syndrome effect and incidence of adverse events were compared between the two groups two and four weeks after treatment.Results:At two and four weeks after treatment,the myocardial injury markers of creatine kinase isoenzyme(CKMB),troponin(cTnI)and aspartate aminotransferase(AST)in observation group were better than those in control group(all P<0.05),the cardiac function indexes of NT-B-type natriuretic peptide precursor(NT-proBNP),left ventricular systolic index(LVEF)and left ventricular end-diastolic diameter(LVEDD)were better than those of control group(all P<0.05),the inflammatory indexes C-reactive protein(CRP),erythrocyte sedimentation rate(ESR),interleukin-6(IL-6),ferritin(SF)and lymphocyte count(LY)were better than those of control group(all P<0.05).The total effective rates of arrhythmia in the observation group were 70.00% and 83.33%,which were higher than 46.67% and 63.33% in the control group(all P<0.05).The total effective rate of TCM syndrome in observation group was 76.67% and 93.33%,which was higher than that of control group 56.67% and 70.00%(all P<0.05).Conclusion:Xiaochaihu decoction combined with Zhigancao decoction in the treatment of COVID-19 related VMC can improve myocardial injury,protect heart function,reduce inflammatory response and improve arrhythmia.

参考文献/References:

[1] 汪璐芸,赵春霞,王峰,等.做好新型冠状病毒相关心肌炎的识别、诊断与救治挽救更多生命[J].中华心血管病杂志,2023,51(4):338-342.
[2] AMMIRATI E,LUPI L,PALAZZINI M,et al.Prevalence,characteristics,and outcomes of COVID-19-associated acute myocarditis[J].Circulation,2022,145(15):1123-1139.
[3] COMMITTEE W,GLUCKMANT J,BHAVEN M,et al.2022 ACC expert consensus decision pathway on cardiovascular sequelae of COVID-19 in adults:Myocarditis and other myocardial involvement,post-acute sequelae of SARS-CoV-2 infection,and return to play:A report of the American college of cardiology solution set oversight committee[J].J Am Coll Cardiol,2022,79(17):1717-1756.
[4] RUAN Q,YANG K,WANG W,et al.Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan,China[J].Intensive Care Med,2020,46(5):846-848.
[5] PUNTMANN V O,CARERJ M L,WIETERS I,et al.Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019(COVID-19)[J].JAMA Cardiol,2020,5(11):1265-1273.
[6] 中华人民共和国国家卫生健康委员会.新型冠状病毒感染诊疗方案(试行第十版)[J].中华临床感染病杂志,2023,16(1):1-9.
[7] 国家老年医学中心,中国老年医学学会心电与心功能分会,北京医学会心血管病学分会影像学组,等.新型冠状病毒感染相关心肌损伤、心肌炎和感染后状态管理专家共识(第二版)[J].中国全科医学,2023,26(14):1692-1702.
[8] 中华中医药学会.中医内科常见病诊疗指南[M].北京:中国中医药出版社,2008:58-62.
[9] 李赛美,李宇航.伤寒论讲义(第四版)[M].北京:人民卫生出版社出版,2021:155-161.
[10] 孙传兴.临床疾病诊断依据治愈好转标准第2版[M].北京:人民军医出版社,1992,265-267.
[11] 张军平.病毒性心肌炎中西医结合诊疗实践[M].北京:中国中医药出版社,2014:347-354.
[12] 国家食品药品监督管理总局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:233-237.
[13] 中国医师协会心血管内科医师分会.新型冠状病毒感染与心血管疾病诊疗中国专家共识(2023)[J].中华心血管病杂志(网络版)[J].2023,6(1):1-22.
[14] 中国医师协会心力衰竭专业委员会,中华心力衰竭和心肌病杂志编辑委员会.新型冠状病毒感染相关性心肌炎诊断与治疗中国专家建议[J].中华心力衰竭和心肌病杂志,2022,6(4):280-287.
[15] BHAT R A,MAQBOOL S,RATHI A,et al.The effects of the SARS-CoV-2 virus on the cardiovascular system and coagulation state leading to cardiovascular diseases:A narrative review[J].Inquiry,2022,59:469580221093442.
[16] RUGGIERO R,BALZANO N,DINAPOLI R,et al.Capillary leak syndrome following COVID-19 vaccination:Data from the European pharmacovigilance database eudravigilance[J].Front Immunol,2022,13:956825.
[17] HUANG C,WANG Y,LI X,et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J].Lancet,2020,395(10223):497-506.
[18] 林荣梅,陆霓虹.新型冠状病毒感染相关心肌损伤研究现状[J].结核与肺部疾病杂志,2023,4(6):493-498.
[19] FOXS E,LAMEIRAF S,RINKERE B,et al.Cardiac endotheliitis and multisystem inflammatory syndrome after COVID-19[J].Ann Intern Med,2020,173(12):1025-1027.
[20] SZEKELY Y,LICHTER Y,TAIEB P,et al.Spectrum of cardiac manifestations in COVID-19:A systematic echocardiographic study[J].Circulation,2020,142(4):342-353.
[21] 肖开虎,税莉莉,庞小华,等.重庆市渝东北片区143例2019冠状病毒病患者临床特征分析[J].第三军医大学学报,2020,42(6):549-554.
[22] PINTO-FILHO M M,PAIXAO G M,GOMES P R,et al.Electrocardiographic findings and prognostic values in patients hospitalised with COVID-19 in the world heart federation global study[J].Hear,2023,109(9):668-673.
[23] 马明仁,蔡晓庆,张鹏,等.336例COVID-19患者心律失常与炎症因子相关性分析[J].西北国防医学杂志,2021,42(7):671-674.
[24] 杨璐,崔换天,刘相国,等.基于网络药理学的小柴胡汤治疗新型冠状病毒肺炎(COVID-19)发热的可行性探讨[J].中草药,2020,51(7):1761-1775.
[25] 谌攀,饶鸿宇,吴灏,等.基于分子对接法和网络药理学揭示小柴胡汤防治新型冠状病毒肺炎的活性成分及作用机制[J].中国现代应用药学,2021,38(21):2665-2674.
[26] 刘颖,谢淑萍.炙甘草汤对病毒性心肌炎患者心功能及炎性因子水平的影响[J].光明中医,2022,37(17):3147-3149.
[27] 丁立峰,张国海.炙甘草汤加味治疗病毒性心肌炎疗效观察[J].现代中西医结合杂志,2009,18(7):762.

相似文献/References:

[1]雷 霏,高彩霞.小柴胡汤加减对代谢相关性脂肪性肝病患者肝功能及胰岛素抵抗的影响[J].陕西中医,2022,(7):890.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.018]
　LEI Fei,GAO Caixia.Effect of modified Xiaochaihu decoction on liver function and insulin resistance in patients with metabolic-related fatty liver disease[J].,2022,(12):890.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.018]
[2]李悦斐,许 坚,陈武君,等.小柴胡汤联合痰热清治疗肺心病疗效及对患者炎症因子的影响[J].陕西中医,2022,(12):1709.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.013]
　LI Yuefei,XU Jian,CHEN Wujun,et al.Effect of Xiaochaihu decoction combined with Tanreqing on pulmonary heart disease and its influence on inflammatory factors[J].,2022,(12):1709.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.013]
[3]田 菲,张晓杰,苗春澍,等.小柴胡汤合五苓散治疗慢性湿疹疗效及对患者中医证候积分和焦虑、抑郁状态的影响[J].陕西中医,2023,(6):738.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.012]
　TIAN Fei,ZHANG Xiaojie,MIAO Chunshu,et al.Efficacy of Xiaochaihu decoction with Wuling powder in the treatment of patients with chronic eczema and its effects on TCM syndromes scores and anxiety and depression[J].,2023,(12):738.[doi:DOI:10.3969/j.issn.1000-7369.2023.06.012]
[4]袁 冰,袁 洁,黄凯琳,等.基于“心脾相关,调气为先”探讨双心病中医治疗[J].陕西中医,2024,(11):1529.[doi:DOI:10.3969/j.issn.1000-7369.2024.11.019]
　YUAN Bing,YUAN Jie,HUANG Kailin,et al.Based on “heart-spleen correlation,regulating Qi first” to explore Chinese medicine treatment of double heart disease[J].,2024,(12):1529.[doi:DOI:10.3969/j.issn.1000-7369.2024.11.019]

备注/Memo

备注/Memo:
基金项目:广西壮族自治区中医药管理局科研课题(GXZYB20230480)
更新日期/Last Update: 2024-12-05